Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-κB signaling pathway.

Rathore M, Girard C, Ohanna M, Tichet M, Ben Jouira R, Garcia E, Larbret F, Gesson M, Audebert S, Lacour JP, Montaudié H, Prod'Homme V, Tartare-Deckert S, Deckert M.

Oncogene. 2019 Jul;38(30):5873-5889. doi: 10.1038/s41388-019-0848-9. Epub 2019 Jun 28.

PMID:
31253871
2.

Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas.

Garandeau D, Noujarède J, Leclerc J, Imbert C, Garcia V, Bats ML, Rambow F, Gilhodes J, Filleron T, Meyer N, Brayer S, Arcucci S, Tartare-Deckert S, Ségui B, Marine JC, Levade T, Bertolotto C, Andrieu-Abadie N.

Mol Cancer Ther. 2019 Feb;18(2):289-300. doi: 10.1158/1535-7163.MCT-17-1141. Epub 2018 Nov 27.

PMID:
30482853
3.

Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting Therapies.

Didier R, Mallavialle A, Ben Jouira R, Domdom MA, Tichet M, Auberger P, Luciano F, Ohanna M, Tartare-Deckert S, Deckert M.

Mol Cancer Ther. 2018 Jul;17(7):1416-1429. doi: 10.1158/1535-7163.MCT-17-0919. Epub 2018 Apr 27.

4.

A non-coding function of TYRP1 mRNA promotes melanoma growth.

Gilot D, Migault M, Bachelot L, Journé F, Rogiers A, Donnou-Fournet E, Mogha A, Mouchet N, Pinel-Marie ML, Mari B, Montier T, Corre S, Gautron A, Rambow F, El Hajj P, Ben Jouira R, Tartare-Deckert S, Marine JC, Felden B, Ghanem G, Galibert MD.

Nat Cell Biol. 2017 Nov;19(11):1348-1357. doi: 10.1038/ncb3623. Epub 2017 Oct 9.

5.

Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma.

Olvedy M, Tisserand JC, Luciani F, Boeckx B, Wouters J, Lopez S, Rambow F, Aibar S, Thienpont B, Barra J, Köhler C, Radaelli E, Tartare-Deckert S, Aerts S, Dubreuil P, van den Oord JJ, Lambrechts D, De Sepulveda P, Marine JC.

J Clin Invest. 2017 Jun 1;127(6):2310-2325. doi: 10.1172/JCI91291. Epub 2017 May 2.

6.

SIGMAR1 Regulates Membrane Electrical Activity in Response to Extracellular Matrix Stimulation to Drive Cancer Cell Invasiveness.

Crottès D, Rapetti-Mauss R, Alcaraz-Perez F, Tichet M, Gariano G, Martial S, Guizouarn H, Pellissier B, Loubat A, Popa A, Paquet A, Presta M, Tartare-Deckert S, Cayuela ML, Martin P, Borgese F, Soriani O.

Cancer Res. 2016 Feb 1;76(3):607-18. doi: 10.1158/0008-5472.CAN-15-1465. Epub 2015 Dec 8.

7.

Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis.

Tichet M, Prod'Homme V, Fenouille N, Ambrosetti D, Mallavialle A, Cerezo M, Ohanna M, Audebert S, Rocchi S, Giacchero D, Boukari F, Allegra M, Chambard JC, Lacour JP, Michiels JF, Borg JP, Deckert M, Tartare-Deckert S.

Nat Commun. 2015 Apr 30;6:6993. doi: 10.1038/ncomms7993.

PMID:
25925867
8.

Cherubism allele heterozygosity amplifies microbe-induced inflammatory responses in murine macrophages.

Prod'Homme V, Boyer L, Dubois N, Mallavialle A, Munro P, Mouska X, Coste I, Rottapel R, Tartare-Deckert S, Deckert M.

J Clin Invest. 2015 Apr;125(4):1396-400. doi: 10.1172/JCI71081. Epub 2015 Feb 23.

9.

Risk for nevus transformation and melanoma proliferation and invasion during natalizumab treatment: four years of dermoscopic follow-up with immunohistological studies and proliferation and invasion assays.

Pharaon M, Tichet M, Lebrun-Frénay C, Tartare-Deckert S, Passeron T.

JAMA Dermatol. 2014 Aug;150(8):901-3. doi: 10.1001/jamadermatol.2013.9411. No abstract available.

PMID:
24919481
10.

LIF mediates proinvasive activation of stromal fibroblasts in cancer.

Albrengues J, Bourget I, Pons C, Butet V, Hofman P, Tartare-Deckert S, Feral CC, Meneguzzi G, Gaggioli C.

Cell Rep. 2014 Jun 12;7(5):1664-1678. doi: 10.1016/j.celrep.2014.04.036. Epub 2014 May 22.

11.

Technical advance: actin CytoFRET, a novel FRET flow cytometry method for detection of actin dynamics in resting and activated T cell.

Larbret F, Dubois N, Brau F, Guillemot E, Mahiddine K, Tartare-Deckert S, Verhasselt V, Deckert M.

J Leukoc Biol. 2013 Sep;94(3):531-9. doi: 10.1189/jlb.0113022. Epub 2013 Jun 21.

PMID:
23794712
12.

Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner.

Cerezo M, Tichet M, Abbe P, Ohanna M, Lehraiki A, Rouaud F, Allegra M, Giacchero D, Bahadoran P, Bertolotto C, Tartare-Deckert S, Ballotti R, Rocchi S.

Mol Cancer Ther. 2013 Aug;12(8):1605-15. doi: 10.1158/1535-7163.MCT-12-1226-T. Epub 2013 Jun 5.

13.

Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway.

Robert G, Jullian V, Jacquel A, Ginet C, Dufies M, Torino S, Pottier A, Peyrade F, Tartare-Deckert S, Bourdy G, Deharo E, Auberger P.

Oncotarget. 2012 Dec;3(12):1688-99.

14.

The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion.

Fenouille N, Tichet M, Dufies M, Pottier A, Mogha A, Soo JK, Rocchi S, Mallavialle A, Galibert MD, Khammari A, Lacour JP, Ballotti R, Deckert M, Tartare-Deckert S.

PLoS One. 2012;7(7):e40378. doi: 10.1371/journal.pone.0040378. Epub 2012 Jul 20.

15.

Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells.

Cheli Y, Giuliano S, Fenouille N, Allegra M, Hofman V, Hofman P, Bahadoran P, Lacour JP, Tartare-Deckert S, Bertolotto C, Ballotti R.

Oncogene. 2012 May 10;31(19):2461-70. doi: 10.1038/onc.2011.425. Epub 2011 Sep 26.

PMID:
21996743
16.

Metformin inhibits melanoma development through autophagy and apoptosis mechanisms.

Tomic T, Botton T, Cerezo M, Robert G, Luciano F, Puissant A, Gounon P, Allegra M, Bertolotto C, Bereder JM, Tartare-Deckert S, Bahadoran P, Auberger P, Ballotti R, Rocchi S.

Cell Death Dis. 2011 Sep 1;2:e199. doi: 10.1038/cddis.2011.86.

17.

SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival.

Fenouille N, Puissant A, Tichet M, Zimniak G, Abbe P, Mallavialle A, Rocchi S, Ortonne JP, Deckert M, Ballotti R, Tartare-Deckert S.

Oncogene. 2011 Dec 8;30(49):4887-900. doi: 10.1038/onc.2011.198. Epub 2011 Jun 20.

PMID:
21685937
18.

Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC.

Fenouille N, Puissant A, Dufies M, Robert G, Jacquel A, Ohanna M, Deckert M, Pasquet JM, Mahon FX, Cassuto JP, Raynaud S, Tartare-Deckert S, Auberger P.

Cancer Res. 2010 Dec 1;70(23):9659-70. doi: 10.1158/0008-5472.CAN-10-2034. Epub 2010 Nov 23.

19.

The p53/p21Cip1/ Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression.

Fenouille N, Robert G, Tichet M, Puissant A, Dufies M, Rocchi S, Ortonne JP, Deckert M, Ballotti R, Tartare-Deckert S.

Pigment Cell Melanoma Res. 2011 Feb;24(1):219-32. doi: 10.1111/j.1755-148X.2010.00790.x. Epub 2010 Nov 17.

PMID:
20955243
20.

Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth.

Botton T, Puissant A, Cheli Y, Tomic T, Giuliano S, Fajas L, Deckert M, Ortonne JP, Bertolotto C, Tartare-Deckert S, Ballotti R, Rocchi S.

Cell Death Differ. 2011 Jan;18(1):109-21. doi: 10.1038/cdd.2010.75. Epub 2010 Jul 2.

21.

The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.

Baudot AD, Jeandel PY, Mouska X, Maurer U, Tartare-Deckert S, Raynaud SD, Cassuto JP, Ticchioni M, Deckert M.

Oncogene. 2009 Sep 17;28(37):3261-73. doi: 10.1038/onc.2009.179. Epub 2009 Jul 6.

PMID:
19581935
22.

Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest.

Bailet O, Fenouille N, Abbe P, Robert G, Rocchi S, Gonthier N, Denoyelle C, Ticchioni M, Ortonne JP, Ballotti R, Deckert M, Tartare-Deckert S.

Cancer Res. 2009 Apr 1;69(7):2748-56. doi: 10.1158/0008-5472.CAN-08-2690. Epub 2009 Mar 17.

23.

In vitro and in vivo anti-melanoma effects of ciglitazone.

Botton T, Puissant A, Bahadoran P, Annicotte JS, Fajas L, Ortonne JP, Gozzerino G, Zamoum T, Tartare-Deckert S, Bertolotto C, Ballotti R, Rocchi S.

J Invest Dermatol. 2009 May;129(5):1208-18. doi: 10.1038/jid.2008.346. Epub 2009 Jan 29.

24.

Regulation of secreted protein acidic and rich in cysteine during adipose conversion and adipose tissue hyperplasia.

Chavey C, Boucher J, Monthouël-Kartmann MN, Sage EH, Castan-Laurell I, Valet P, Tartare-Deckert S, Van Obberghen E.

Obesity (Silver Spring). 2006 Nov;14(11):1890-7.

25.

Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway.

Gaggioli C, Robert G, Bertolotto C, Bailet O, Abbe P, Spadafora A, Bahadoran P, Ortonne JP, Baron V, Ballotti R, Tartare-Deckert S.

J Invest Dermatol. 2007 Feb;127(2):400-10. Epub 2006 Sep 7.

26.

SPARC represses E-cadherin and induces mesenchymal transition during melanoma development.

Robert G, Gaggioli C, Bailet O, Chavey C, Abbe P, Aberdam E, Sabatié E, Cano A, Garcia de Herreros A, Ballotti R, Tartare-Deckert S.

Cancer Res. 2006 Aug 1;66(15):7516-23.

27.

HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1.

Gaggioli C, Deckert M, Robert G, Abbe P, Batoz M, Ehrengruber MU, Ortonne JP, Ballotti R, Tartare-Deckert S.

Oncogene. 2005 Feb 17;24(8):1423-33.

PMID:
15608673
28.

Pathological prion protein exposure switches on neuronal mitogen-activated protein kinase pathway resulting in microglia recruitment.

Marella M, Gaggioli C, Batoz M, Deckert M, Tartare-Deckert S, Chabry J.

J Biol Chem. 2005 Jan 14;280(2):1529-34. Epub 2004 Nov 4.

29.

PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes.

Larribere L, Khaled M, Tartare-Deckert S, Busca R, Luciano F, Bille K, Valony G, Eychene A, Auberger P, Ortonne JP, Ballotti R, Bertolotto C.

Cell Death Differ. 2004 Oct;11(10):1084-91.

30.

Gene expression profiling of normal human pulmonary fibroblasts following coculture with non-small-cell lung cancer cells reveals alterations related to matrix degradation, angiogenesis, cell growth and survival.

Fromigué O, Louis K, Dayem M, Milanini J, Pages G, Tartare-Deckert S, Ponzio G, Hofman P, Barbry P, Auberger P, Mari B.

Oncogene. 2003 Nov 20;22(52):8487-97.

PMID:
14627989
31.

Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation.

Chavey C, Mari B, Monthouel MN, Bonnafous S, Anglard P, Van Obberghen E, Tartare-Deckert S.

J Biol Chem. 2003 Apr 4;278(14):11888-96. Epub 2003 Jan 15.

32.

Prostaglandin E2 induces interaction between hSlo potassium channel and Syk tyrosine kinase in osteosarcoma cells.

Rezzonico R, Schmid-Alliana A, Romey G, Bourget-Ponzio I, Breuil V, Breittmayer V, Tartare-Deckert S, Rossi B, Schmid-Antomarchi H.

J Bone Miner Res. 2002 May;17(5):869-78.

33.

Dual roles of p300 in chromatin assembly and transcriptional activation in cooperation with nucleosome assembly protein 1 in vitro.

Asahara H, Tartare-Deckert S, Nakagawa T, Ikehara T, Hirose F, Hunter T, Ito T, Montminy M.

Mol Cell Biol. 2002 May;22(9):2974-83.

34.

Vav1 couples T cell receptor to serum response factor-dependent transcription via a MEK-dependent pathway.

Charvet C, Auberger P, Tartare-Deckert S, Bernard A, Deckert M.

J Biol Chem. 2002 May 3;277(18):15376-84. Epub 2002 Feb 21.

35.

Surfing the insulin signaling web.

Van Obberghen E, Baron V, Delahaye L, Emanuelli B, Filippa N, Giorgetti-Peraldi S, Lebrun P, Mothe-Satney I, Peraldi P, Rocchi S, Sawka-Verhelle D, Tartare-Deckert S, Giudicelli J.

Eur J Clin Invest. 2001 Nov;31(11):966-77. Review.

PMID:
11737239
36.

The matricellular protein SPARC/osteonectin as a newly identified factor up-regulated in obesity.

Tartare-Deckert S, Chavey C, Monthouel MN, Gautier N, Van Obberghen E.

J Biol Chem. 2001 Jun 22;276(25):22231-7. Epub 2001 Apr 9.

37.

Vav2 activates c-fos serum response element and CD69 expression but negatively regulates nuclear factor of activated T cells and interleukin-2 gene activation in T lymphocyte.

Tartare-Deckert S, Monthouel MN, Charvet C, Foucault I, Van Obberghen E, Bernard A, Altman A, Deckert M.

J Biol Chem. 2001 Jun 15;276(24):20849-57. Epub 2001 Mar 21.

38.

Stat 5B, activated by insulin in a Jak-independent fashion, plays a role in glucokinase gene transcription.

Sawka-Verhelle D, Tartare-Deckert S, Decaux JF, Girard J, Van Obberghen E.

Endocrinology. 2000 Jun;141(6):1977-88.

PMID:
10830280
39.

Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site.

Geneste O, Bidaud C, De Vita G, Hofstra RM, Tartare-Deckert S, Buys CH, Lenoir GM, Santoro M, Billaud M.

Hum Mol Genet. 1999 Oct;8(11):1989-99.

PMID:
10484767
40.

C-terminal Src kinase associates with ligand-stimulated insulin-like growth factor-I receptor.

Arbet-Engels C, Tartare-Deckert S, Eckhart W.

J Biol Chem. 1999 Feb 26;274(9):5422-8.

41.

Adaptor function for the Syk kinases-interacting protein 3BP2 in IL-2 gene activation.

Deckert M, Tartare-Deckert S, Hernandez J, Rottapel R, Altman A.

Immunity. 1998 Nov;9(5):595-605.

42.

Determination of Gab1 (Grb2-associated binder-1) interaction with insulin receptor-signaling molecules.

Rocchi S, Tartare-Deckert S, Murdaca J, Holgado-Madruga M, Wong AJ, Van Obberghen E.

Mol Endocrinol. 1998 Jul;12(7):914-23.

PMID:
9658397
43.

Identification of Stat 5B as a substrate of the insulin receptor.

Sawka-Verhelle D, Filloux C, Tartare-Deckert S, Mothe I, Van Obberghen E.

Eur J Biochem. 1997 Dec 1;250(2):411-7.

44.

Evidence for a direct interaction between insulin receptor substrate-1 and Shc.

Kasus-Jacobi A, Perdereau D, Tartare-Deckert S, Van Obberghen E, Girard J, Burnol AF.

J Biol Chem. 1997 Jul 4;272(27):17166-70.

45.

Functional and physical interactions of Syk family kinases with the Vav proto-oncogene product.

Deckert M, Tartare-Deckert S, Couture C, Mustelin T, Altman A.

Immunity. 1996 Dec;5(6):591-604.

46.
47.
49.
50.

Supplemental Content

Loading ...
Support Center